References
- Hedner T., Kjeldsen S. E., Narkiewicz K., Oparil S. Blood pressure control–slowly getting there through new strategies?. Blood Press 2007; 16: 68–71
- Hedner T., Narkiewicz K., Kjeldsen S. E. There is a need for more aggressive implementation of combination strategies to control hypertensive risk. Blood Press (Suppl 1) 2007; 1: 4–5
- Jamerson K. A., Bakris G. L., Wun C. C., Dahlöf B., Lefkowitz M., Manfreda S., et al. Rationale and Design of the Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial. Am J Hypertens 2004; 17: 793–801
- Weber M. A., Bakris G. L., Dahlöf B., Pitt B., Velazques E. J., Gupte J., et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Press 2007; 16: 13–19
- Jamerson K. A., Bakris G. L., Dahlof B., Pitt B., Velazques E. J., Gupte J., et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press 2007; 16: 80–6
- Kjeldsen S. E., Jamerson K. A., Bakris G. L., Pitt B., Bahlöf B., Velazques E. J., , for the ACCOMPLISH Investigators, et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH Study. Blood Press 2008; 17: 7–17
- Kjeldsen S. E., Oparil S., Narkiewicz K., Hedner T. A stunning day in hypertension research – results of ONTARGET, ACCOMPLISH and HYVET. Blood Press 2008; 17: 68–9
- Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin‐converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high‐risk patients. N Engl J Med 2000; 342: 145–53
- Dickstein K., Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60
- Pfeffer M. A., McMurray J. J. V., Velazquez E. J., et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1905
- Pitt B., Segal R., Martinez F. A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52
- Pitt B., Poole‐Wilson P. A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial–the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7
- Granger C. B., McMurray J. J., Yusuf S., et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function intolerant to angiotensin‐converting‐enzyme inhibitors: the CHARM‐Alternative trial. Lancet 2003; 362: 772–6
- Voors A. A., van Veldhuisen D. J. Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. Int J Cardiol 2004; 97: 345–8
- McKelvie R. S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–64
- Matchar D. B., McCrory D. C., Orlando L. A., et al. Systematic review: comparative effectiveness of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16–29